课题基金 / 基金详情

In vivo persistence and immuno-pathogenesis of Mycobacterium abscessus in a new Xenopus tadpole model

In vivo persistence and immuno-pathogenesis of Mycobacterium abscessus in a new Xenopus tadpole model
脓肿分枝杆菌在新爪蟾蝌蚪模型中的体内持久性和免疫发病机制
批准号:
10608077
负责人:
Martin S. Pavelka
金额:
$19.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-11 至 2024-03-31

项目摘要

项目成果

Martin S. Pavelka的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Owing to its increasing prevalence, persistence, multidrug resistance, pathogenicity and treatment challenges, the non-tuberculosis mycobacterium (NTM) Mycobacterium abscessus (Mab) has become a serious threat to humans with chronic lung diseases such as bronchiectasis and cystic fibrosis, as well as immunocompromised patients. However, Mab is still understudied compared to other pathogenic mycobacteria. In addition, there is a limitation in current animal models that poses a real challenge for investigating the respective roles of two Mab morphotypes, smooth (S) and rough (R), in lung immunopathology, persistence and host immune response. The clearance of Mab in immunocompetent and even immunocompromised mice prevent the study of chronic infection, and while for zebrafish embryos are instrumental for investigating Mab infection, they cannot be used to model a pulmonary infection and T cell involvement. Thus, there is a need for complementary animal models. Since like zebrafish embryos, X. laevis tadpoles are transparent, allowing visualization of pathogen dissemination, but that in addition they do have functional lungs and exhibit an immune system including T cells remarkably similar to humans, we propose to develop a X. laevis tadpole model of Mab infection that mimics human pulmonary disease. Relying on an established comparative biology approach to study immunity to mycobacteria in tadpoles and our recent demonstration that both S and R Mab morphotypes readily infect tadpoles, disseminate in tadpole lungs and persist up to 50 days, the objective of the exploratory research proposal is to investigate in vivo for over 40 days Mab persistence, and immuno-pathogenesis. Specifically, to address the hypothesis that persistent R Mab is more actively proliferating and immunopathogenic than S Mab in X. laevis tadpoles we propose: , by comparing the host immune response and persistence of R and S Mab in the lung and other tissues using intravital (1) Characterize immune-pathogenesis in tadpole lungs during persisting Mab infection microscopy flow cytometry and transcriptomics as well as fluorescently labeled Mab and transgenic tadpoles with fluorescent macrophages. (2) Investigate the relevance of S to R morphotype switch in vivo for pathogenesis and persistence , by using a promoter system to control the S to R switch following infection and examining effect of switches on persistence, pathogenicity and host immune response. (3) Investigate genetic determinants of Mab immune-pathogenesis , using selected Mab deletion mutants generated by allelic exchange of Mab-specific genes as well as gene homologs shared by Gram- negative lung pathogens. We anticipate that novel insights relevant to human will be gathered. Our collaborative team is uniquely positioned to carry these studies due to our background and complementary expertise.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo persistence and immuno-pathogenesis of Mycobacterium abscessus in a new Xenopus tadpole model
  • 批准号:
    10350750
  • 项目类别:
  • 资助金额:
    $23.1万
  • 财政年份:
    2022
  • 负责人:
    Martin S. Pavelka
  • 依托单位:
Analysis of a novel peptidoglycan assembly pathway in mycobacteria
  • 批准号:
    10203747
  • 项目类别:
  • 资助金额:
    $44.15万
  • 财政年份:
    2018
  • 负责人:
    Martin S. Pavelka
  • 依托单位:
Analysis of a novel peptidoglycan assembly pathway in mycobacteria
  • 批准号:
    10431963
  • 项目类别:
  • 资助金额:
    $44.15万
  • 财政年份:
    2018
  • 负责人:
    Martin S. Pavelka
  • 依托单位:
New tools for studying M. abscessus pathogenesis
  • 批准号:
    8814644
  • 项目类别:
  • 资助金额:
    $27.35万
  • 财政年份:
    2015
  • 负责人:
    Martin S. Pavelka
  • 依托单位:
海外基金